8:26 AM
 | 
Jan 12, 2018
 |  BC Week In Review  |  Company News  |  Other News

Shire to split neuro and rare disease businesses

Shire plc (LSE:SHP; NASDAQ:SHPG) said it will split its neuroscience and rare disease businesses into two divisions. The separation comes after the pharma said in its 2Q17 earnings report that it was evaluating options for its neurology franchise (see BioCentury, Aug. 4, 2017).

CEO Flemming Ornskov announced the changes Jan. 8 at the J.P. Morgan Healthcare Conference in San Francisco, saying that establishing the two divisions would be the company's focus for 1H18. In August, Shire...

Read the full 361 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >